DL-Ethyl 2-bromobutyrate

We are DL-Ethyl 2-bromobutyrate CAS:533-68-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:DL-Ethyl 2-bromobutyrate
CAS.NO:533-68-6
Synonyms:2-Bromobutanoic Acid Ethyl Ester
Ethyl 2-bromobutyrate
Molecular Formula:C6H11BrO2
Molecular Weight:195.05400
 
Physical and Chemical Properties:
Density:1.321;
Melting point:-4oC;
Boiling point:177oC;
Flash point:137oF;
Index of Refraction:1.447;
 
Specification:
Appearance:Colorless to pale yellow Clear liquid
Purity(GC):≥98.0%
Moisture:≤0.1%
 
Packing:250 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As an intermediate in pesticides and medicines
 

DL-Ethyl 2-bromobutyrate


Related News: Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more.93-68-5 The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China’s public hospitals, where most Chinese people buy their drugs.N-BUTYLTRIMETHOXYSILANE CAS:1067-57-8 The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China’s public hospitals, where most Chinese people buy their drugs.Ácido (2S) -3- (4-carbamoil-2,6-dimetilfenil) -2 – [(2-metilpropan-2-il) oxicarbonilamino] propanoico CAS:623950-02-7 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.

Related Products
Product Name
BOC-L-Serine View Details
Deslorelin View Details
delta-Valerolactone View Details
3-Aminophenylacetylene manufacturer 2-Chloro-3-methoxypyridine manufacturer Ethyl 2-(triphenylphosphoranylidene)propionate manufacturer 4-methylsalicylic acid manufacturer (4R,6R)-tert-Butyl-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate manufacturer